Meet an Unreasonable Venture
CyanoCapture
Next generation oral GLP-1 drug delivery technology.
CyanoCapture, subsidiary of General Biotechnologies (2026), reduces the cost of peptide drug manufacturing globally.
The genetic engineering technology developed at Oxford, turns photosynthetic microbes into microscopic factories that can produce complex drug molecules according to instructions encoded in the inserted DNA. These edible microbes can contain peptide drugs such as GLP-1s and deliver them into the gut, without the need for injections.
Notable Achievements
- Launching the US' first manufacturing of oral GLP-1 in Sacramento (Q3 2026).
- Secured $27m in LOIs and pre-orders to supply growth factors and insulin.
- Winner of the Elon Musk's Carbon Removal XPRIZE 2021.
Currently Operating in Three Regions
Press Mentions
February 18, 2026
CyanoCapture and Persist AI Announce Strategic Collaboration to Build World's First Robotic GMP Facility for Oral Protein and Peptide Drugs
CyanoCapture has partnered with Persist AI to develop the world's first robotic GMP facility for producing oral protein and peptide drugs. This collaboration highlights CyanoCapture's commitment to...
Read more »
October 30, 2025
Liverpool, CyanoCapture Team Up for Bionanotech Breakthrough
CyanoCapture collaborates with Liverpool researchers to advance bionanotechnology, focusing on enhancing carbon capture technologies through innovative cyanobacteria. This partnership aims to...
Read on Mirage News »More Ventures in Energy & Environment
Get the Unreasonable Newsletter
Get monthly updates on CyanoCapture and all of the other ventures working to solve global challenges.